Part 1 – Asymptomatic COVID-19 Testing

September 9, 2020

Learning Objectives

Upon completion of this webinar recording, participants will better understand:

  • Review the definition of Laboratory Developed Tests, LDTs
  • Understand CLIA and FDA regulations surrounding LDTs
  • Review current Legislative Proposals that could impact the regulations surrounding LDTs: the VITAL Act and the VALID Act
  • Discuss the HHS announcement
  • Understand staffing and CLIA complexity requirements to perform LDTs
  • Review recent COVID lab market updates


  • Kimberly Zunker, Consulting Manager at Accumen
  • Jon Harol, President at Lighthouse Labs